| Recruiting | Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transpla NCT06916195 | MSD Italia S.r.l. | — |
| Recruiting | Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections NCT06334497 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Withdrawn | A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients NCT06133010 | ModernaTX, Inc. | Phase 2 |
| Recruiting | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in All NCT05683457 | ModernaTX, Inc. | Phase 2 |
| Completed | A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in NCT05763823 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 NCT05105048 | ModernaTX, Inc. | Phase 1 |
| Terminated | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Hea NCT05085366 | ModernaTX, Inc. | Phase 3 |
| Recruiting | A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection NCT04706923 | SymBio Pharmaceuticals | Phase 2 |
| Completed | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vacci NCT04975893 | ModernaTX, Inc. | Phase 2 |
| Completed | Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Hea NCT04232280 | ModernaTX, Inc. | Phase 2 |
| Completed | MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese NCT04129398 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (C NCT03930615 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Dried Blood Spot Testing of CMV Detection in HCT Recipients NCT03910478 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adul NCT03382405 | ModernaTX, Inc. | Phase 1 |
| Withdrawn | Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation NCT02702427 | St. Anna Kinderkrebsforschung | Phase 1 / Phase 2 |
| Completed | Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV NCT02798692 | Hookipa Biotech GmbH | Phase 1 |
| Unknown | Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After H NCT03210090 | Maimónides Biomedical Research Institute of Córdoba | — |
| Completed | Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers NCT02454699 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss NCT01649869 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients NCT02156479 | Lophius Biosciences GmbH | — |
| Completed | Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With NCT02328963 | University Hospital, Bordeaux | Phase 4 |
| Completed | Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus NCT01941056 | City of Hope Medical Center | Phase 1 |
| Completed | An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Su NCT02103426 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") NCT01552369 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipie NCT01354301 | Hospital do Rim e Hipertensão | Phase 4 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Alternate Donor Study of Pre-Emptive Cellular Therapy NCT01220895 | Cell Medica Ltd | Phase 2 |
| Completed | Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk t NCT01178905 | University Hospital Tuebingen | N/A |
| Unknown | Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients NCT01473849 | Sociedad Española de Trasplante Hepático | — |
| Completed | Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipien NCT00942305 | Jazz Pharmaceuticals | Phase 2 |
| Terminated | In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir NCT01037712 | Assistance Publique - Hôpitaux de Paris | Phase 4 |
| Completed | Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection NCT00881517 | Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 2 / Phase 3 |
| Completed | Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus NCT00880789 | Baylor College of Medicine | Phase 1 |
| Unknown | Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy NCT00966836 | University of Bologna | Phase 3 |
| Completed | Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study NCT01077908 | Cell Medica Ltd | Phase 3 |
| Completed | Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections NCT00466817 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Re NCT00817908 | University of Alberta | — |
| Completed | Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients NCT00699868 | Assistance Publique Hopitaux De Marseille | N/A |
| Completed | Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge NCT00373412 | University of California, San Francisco | Phase 1 |
| Completed | Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM NCT00370006 | University of California, San Francisco | Phase 1 |
| Completed | Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovir NCT00400322 | Karolinska Institutet | N/A |
| Completed | TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant NCT00386412 | PETHEMA Foundation | Phase 2 |
| Completed | A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients. NCT00273143 | Mayo Clinic | — |
| Completed | Maribavir for Prevention of CMV After Stem Cell Transplants NCT00223925 | Shire | Phase 2 |
| Completed | Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients NCT00730769 | Salvador Gil-Vernet | Phase 4 |
| Completed | Cytomegalovirus (CMV) Infection in Pregnancy NCT00194155 | University of Pennsylvania | — |
| Completed | Study of Prophylactic Vs Preemptive Valganciclovir NCT00374686 | Washington University School of Medicine | N/A |
| Completed | Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts NCT00023036 | National Institute on Deafness and Other Communication Disorders (NIDCD) | — |
| Completed | Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients NCT00373165 | Lower Saxony Center for Nephrology | Phase 4 |
| Completed | Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection NCT00001976 | National Institute of Allergy and Infectious Diseases (NIAID) | — |